Trial Profile
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2018 Planned End Date changed from 1 Nov 2019 to 20 Nov 2026.
- 18 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 20 Nov 2025.